ACIUHealthcare · BiotechnologyThe 4 Wall Street analysts covering AC Immune SA hold a median 12-month price target of $8.42 — +230.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores AC Immune SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (64): Smaller than most of the companies we track.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ACIU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +230.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | BTIG | Reiterates | Buy | $8.00 |
| 20 Aug 2026 | BTIG | Reiterates | Buy | $8.00 |
| 20 Aug 2026 | BTIG | Reiterates | Buy | — |
| 5 Aug 2026 | BTIG | Reiterates | Buy | $8.00 |
| 5 Aug 2026 | BTIG | Reiterates | Buy | — |
| 4 May 2026 | BTIG | Reiterates | Buy | $8.00 |
| 4 May 2026 | BTIG | Reiterates | Buy | — |
| 16 Mar 2026 | BTIG | Reiterates | Buy | — |
| 4 Nov 2025 | BTIG | Reiterates | Buy | — |
| 8 Sept 2025 | BTIG | Reiterates | Buy | — |
| 1 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2025 | HC Wainwright& Co. | Reiterates | Buy | — |
| 14 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2024 | BTIG | Initiates | Buy | — |
| 15 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACIU appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, AC Immune SA returned −27.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 11% of US stocks
Cheaper than 17% of US stocks
Cheaper than 78% of US stocks
Higher than 99% of US stocks
Higher than 97% of US stocks
Higher than 60% of US stocks
Higher than 2% of US stocks
Higher than 16% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AC Immune SA has a market value of $250.6M and an enterprise value of $215.7M.
Revenue in the twelve months to 30 June 2026: $17.5M. The latest quarter grew 1057.2% year on year.
Net income over the same four quarters: −$43.2M, a −246.5% net margin.
Trailing P/E: −3.6×; forward P/E: 4.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AC Immune SA employs 90 people — $195K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AC Immune SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AC Immune SA (ACIU) was added to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026, alongside SCL. The ranking was announced by Zacks Investment Research.
Why it matters — The Strong Buy momentum ranking from Zacks signals increased positive attention on ACIU from a widely followed research firm.
AC Immune reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy targeting aggregated alpha-synuclein in early Parkinson's disease. The study met its safety and immunogenicity goals.
Why it matters — For ACIU watchers, this confirms that the lead Parkinson's candidate achieved its early safety and immunogenicity endpoints, a key milestone for the ongoing VacSYn clinical program.
AC Immune reported positive 100-week safety and immunogenicity data for ACI-7104 in early-stage Parkinson's disease, and highlighted pipeline progress including Takeda-partnered ACI-24 for prodromal Alzheimer's (which triggered a $12M milestone) and advancing brain-penetrant NLRP3 inhibitor ACI-19764, with phase 1/1b initial data expected at the end of 2026 and final data in the first half of 2027.
Why it matters — ACI-7104's sustained safety and immunogenicity data, along with multiple advancing pipeline programs and an announced milestone payment, signal continued clinical momentum for AC Immune watchers.
AC Immune announced positive week-100 safety and immunogenicity results from Part 1 of the VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson's disease. All primary endpoints were met, with ACI-7104 generally safe and well tolerated, a 100% immunogenicity response rate after three immunizations, and clear antibody penetration into the cerebrospinal fluid with signals of target engagement. FDA discussions regarding the future development path are planned for early 2027.
Why it matters — The positive Part 1 data supports the ACI-7104 program and its path toward FDA discussions in early 2027, which will inform a potential Phase 3 decision.
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study of ACI-19764, an NLRP3 inhibitor that targets inflammation. The preliminary Phase 1 data were characterized as positive.
Why it matters — This marks early clinical progress for a new pipeline candidate, ACI-19764, that broadens AC Immune's focus into inflammation alongside its existing programmes.
The 4 Wall Street analysts covering AC Immune SA have a median 12-month price target of $8.42, with estimates ranging from $5.35 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering AC Immune SA, 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AC Immune SA 33 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, AC Immune SA ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (64 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +230.2% from the last close, and Ticker Nerd's factor model ranks AC Immune SA 33 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AC Immune SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACIU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.35 to $12 over the next 12 months.
AC Immune SA returned -27.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases. AC Immune SA develops therapeutic and diagnostic products designed to address disorders linked to protein misfolding, with a current emphasis on Alzheimer’s disease, Parkinson’s disease, ALS, and selected rare neurodegenerative conditions.
The most recent item we track (Zacks Investment Research, 30 Sept 2026): "Best Momentum Stock to Buy for September 30th". AC Immune SA (ACIU) was added to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026, alongside SCL. The ranking was announced by Zacks Investment Research.
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases. AC Immune SA develops therapeutic and diagnostic products designed to address disorders linked to protein misfolding, with a current emphasis on Alzheimer’s disease, Parkinson’s disease, ALS, and selected rare neurodegenerative conditions. Its work centers on proprietary technology platforms that support the discovery of antibodies, small molecules, vaccines, and imaging agents intended for early detection, treatment, and prevention. The company’s pipeline spans both therapeutic and diagnostic programs, reflecting a dual approach to understanding disease biology and creating targeted interventions. AC Immune SA also collaborates with pharmaceutical and research partners to advance its programs across neurodegenerative markets. Headquartered in Lausanne, Switzerland, AC Immune SA plays a specialized role in the biotechnology sector by developing tools and treatments aimed at some of the most complex and underserved diseases of the nervous system.
CEO Dr. Martin Zugel M.D., Ph.D. · 90 employees · Switzerland · https://www.acimmune.com
